Journal Home
Search for

Volume 133, Issue 1, Pages 40-48 (January 2003)


View previous. 6 of 28 View next.

Technical complications of continuous intra-arterial chemotherapy with 5-fluorodeoxyuridine and 5-fluorouracil for colorectal liver metastases☆☆

Stefan Heinrich, MD, Henrik Petrowsky, MD, Ingo Schwinnen, MD, Elsbeth Staib-Sebler, MD, Christiane Gog, MD, Ahmed El-Ganainy, MD, Carsten Gutt, MD, Hans-Helge Müller, PhD, Matthias Lorenz, MD

Accepted 19 July 2002.

Abstract 

Background. Intra-arterial chemotherapy is an effective modality to treat unresectable hepatic metastases from colorectal primaries if systemic chemotherapy has failed. Response rates of more than 40% and a median survival of 15 to 25 months have been reported from randomized trials. In this retrospective study, we analyzed specific technical complications associated with continuous intra-arterial chemotherapy for colorectal liver metastases. Methods. From 1982 to 1995, single-center clinical data from 180 patients with colorectal liver metastases were evaluated. Continuous intra-arterial chemotherapy was administered using either an implanted infusion pump or an intra-arterial port with an external infusion pump. The intra-arterial catheter was implanted according to the Watkins' technique. The treatment protocols consisted of 5-fluorouracil- or 5-fluorodeoxyuridine-based regimens. Results. A total of 70 patients (39%) received an intra-arterial infusion pump and 110 patients (61%) an intra-arterial port. Sixty-eight technical complications affected port systems (62%), whereas 29 patients with pumps (41%) were affected by technical complications. Therapy-relevant complications were observed in 47% of the ports and 30% of the infusion pumps. The median complication-free survival was 12.2 months for infusion pumps and 7.3 months for ports (P = .0016). Conclusions. Our data demonstrate that pumps are superior to ports in terms of complication rate and complication-free survival. On the basis of our results, pumps have a potential for a longer treatment, which may result in a prolonged median survival. (Surgery 2003;133:40-8.)

Frankfurt and Marburg, Germany

From the Department of General and Vascular Surgery, University of Frankfurt Medical Center, Frankfurt; and Institute of Medical Biometry and Epidemiology, Philipps University, Marburg, Germany

 Reprint requests: Matthias Lorenz, MD, Department of General and Vascular Surgery, University of Frankfurt Medical Center, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany.

☆☆ 0039-6060/2003/$30.00 + 0

PII: S0039-6060(02)21643-8

doi:10.1067/msy.2003.37


View previous. 6 of 28 View next.